Biotech Values

[vinmantoo]

Doc328,

Thanks for your knowledgable first-hand comments. They reinforce my view that the Q2 numbers aren't that important. What matters is how Daxxify will be taken up with time, and how approval in the CD indication affects uptake in that market.

Given the numbers you cited, does that mean your practice overall isn't very dependent on toxins for patient population and revenues?